Extended Data Table. 1 Patient level baseline, treatment and response characteristics (modified intention-to-treat analysis set)

From: Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results

  1. Data are from the first 37 patients who were treated with CT041 and completed at least 12 weeks follow-up as of the data cutoff date, 08 April 2021. FGC: fludarabine + gemcitabine+ cyclophosphamide; FNC: fludarabine + nab-paclitaxel + cyclophosphamide; GC: gastric cancer including gastroesophageal junction carcinoma; NA: not applicable; PC: pancreatic cancer; PD: progressive disease; PR: partial response; SD: stable disease. #Three drug regimen including 5-Fu, platinum, and paclitaxel was considered as prior 2 lines. **Patients with CLDN18.2 intensity ≤ 2+ or percentage ≥ 40% were enrolled according to protocol version 6.1, in which the inclusion criteria was CLDN18.2 expression intensity ≥ 1+ and percentage ≥10%.
Back to article page